新型质子泵抑制剂艾普拉唑的综合评价与临床应用进展  

Mechanism and Clinical Studies of Ilaprazole

作　　者：刘腾[1] 徐春敏[1] 赵志刚[1] LIU Teng;XU Chun-min;ZHAO Zhi-gang(Department of Pharmacy ,Tiantan Hospital Affiliated to Capital Medical University, Beijing 100050, China)

机构地区：[1]首都医科大学附属北京天坛医院药学部,北京100050

出　　处：《药品评价》2016年第22期8-12,共5页Drug Evaluation

基　　金："药物管理平台"子课题;国家科技部"脑血管病创新药物临床评价技术平台"重大专项基金;编号:2008ZX09312-00

摘　　要：目的:介绍艾普拉唑的作用机制、特点,并评价其临床疗效,为临床合理使用提供理论和循证支持。方法:搜集、整理、分析国内外期刊文献,综述相关的药理学、药动学研究结果,介绍该药国内外上市情况。结果:艾普拉唑可强效抑酸,对CYP2C19酶的抑制作用小,安全性好,对酸相关疾病疗效明确,有较好的经济学优势。结论:艾普拉唑相对前几代的质子泵抑制剂在药理学、药动学方面都具有一定的优势,半衰期最长,减少夜间酸突破(NAB)。在临床疗效上也有所提高,可成为临床抑酸治疗新的用药选择。Objective: Analyze the mechanism of Ilaprazole, measure its clinical effects and characteristics. Provide theoretical and evidence-basedsupport for the rational use of clinical. Method: Collect and analyze the domestic and international periodical literatures. Summary of relevantpharmacological and pharmacokinetic studies, Introduction of the domestic and foreign listing of the drug. Results: Ilaprazole can be potentacid suppression, inhibition of the CYP2C19 enzyme was small, good safety and efficacy of acid related diseases is clear, with a better economy.Conclusion: Compared to previous generations of PPI, Ilaprazole has certain advantages in both Pharmacology and Pharmacokinetics where itimproves the Clinical efficacy , reduce nocturnal acid breakthrough .thus has possibilities to become an alternative to suppress acids.

关 键 词：质子泵抑制剂 艾普拉唑 评价 临床应用 夜间酸突破 半衰期 

分 类 号：R975[医药卫生—药品]